Diagnostic Tests/Kits
Is it COVID-19? Is it Flu? Lab-comparable results in minutes. Verify potential infection quickly with a rapid microfluidic assay that provides actionable and lab-comparable results in 12 mins for patients suspected of Flu and/or COVID-19, to help decision making and guide treatment.
Is it RSV? Is it COVID-19? Actionable results in minutes. Verify potential infection and help guide infection control measures quickly with a rapid microfluidic assay that provides actionable results in 12 minutes, for patients suspected of RSV and/or COVID-19.
Accurately quantitate immunosuppressive drug levels in human whole blood samples with MassTrak Immunosuppressant Calibrator, Quality Control, and Internal Standard sets.
Our unique combination of custom antibody development, lateral flow development and manufacturing services, signal enhancement technology and our mobile diagnostic platform are shaping the future of lateral flow. Our partnership approach allows you to work with one company to reach your assay goals.
BBI Solutions’ Novarumâ„¢ technology transforms a smartphone into a mobile diagnostic platform, empowering users to read and share the results of rapid tests at the point of care. Â
Target Sufficiency® is the ability of a target system to respond to a therapeutic. It reflects the abundance and forms of the drug target protein, as well as other key system proteins that connect the target to disease phenotypes and enable response. Assessment of the target system requires an analysis platform that can simultaneously capture multiple precise protein measurements.
The InviRapid ® lateral flow test strips provide a fast and easy detection of diverse allergens within just a few minutes. These assays are suitable for on-site analysis, and do not require any laboratory equipment. They are user-friendly, even for inexperienced personnel, and can be applied in all stages of the food production process - from testing raw materials to finished good samples, and as part of the surface cleaning…
Determination of total anti-infliximab antibodies Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). The protein can induce humoral immune responses and lead to anti-drug antibody formation, a major cause of loss of drug response. IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.
Determination of total anti-adalimumab antibodies Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, a major cause of loss of drug response. The IDKmonitor Adalimumab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating dru…
Sample Type:Serum; Sample Size:50 µl; Size:96 Wells (LIA); ange:0.25 - 50 ng/ml; Sensitivity:0.1 ng/ml; Incubation Time:30 minutes
